2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3632 Post-transplant lymphoproliferative disorder in Brazil: Clinicopathologic features, EBV association, and outcomes from a single-center cohort

Rafael Henneman Sassi, MD, Rafaella Maria da Cunha Lyrio, MD2, Liane Daudt, MD, PhD3, Tahiane De Brum Soares, MD4, Claudia Astigarraga, MD, PhD5, Alessandra Aparecida Paz, MD6
1 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, Mayo Clinic, Rochester, Minnesota, United States
2 Washington University in St. Louis, St. Louis, Missouri, United States
3 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
4 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
5 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
6 Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

Background:

Post-transplant lymphoproliferative disorder (PTLD) is a rare but potentially fatal complication of solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Data from Latin America are scarce, particularly regarding how the region's high Epstein-Barr virus (EBV) seroprevalence influences PTLD presentation, EBV association, and clinical outcomes.

Methods:

We retrospectively analyzed biopsy-confirmed PTLD diagnosed at Hospital de Clínicas de Porto Alegre, Brazil, between 2018 and 2024. Adult and pediatric recipients of liver, kidney, lung, heart, or allo-HSCT were included; patients with prior lymphoma were excluded. Clinical, transplant, pathology, EBV, treatment, and survival data were extracted from electronic records. All transplant recipients with detectable plasma EBV viral load were additionally evaluated for preemptive Rituximab use and subsequent PTLD development. Institutional PTLD incidence was calculated from the transplant database. Categorical variables were compared using Fisher's exact or Chi-Square tests and continuous variables using the Kruskal-Wallis test with Dunn's post hoc analysis. OS and PFS were estimated by Kaplan-Meier and compared using the log-rank test.

Results:

Thirty-four patients with biopsy-confirmed PTLD were identified. Pediatric liver transplant recipients represented the largest subgroup (15/34), followed by kidney (10/34), allo-HSCT (4/34), lung (3/34), and adult liver transplantation (2/34). Median time from transplantation to PTLD was 3.3 years but differed by transplant type, occurring earliest after allo-HSCT (0.5 years) and lung transplantation (0.6 years), followed by pediatric liver (2.7 years), adult liver (6.0 years), and kidney transplantation (8.3 years) (P<0.01). 

Immunosuppressive regimens were comparable across SOT recipients, whereas allo-HSCT recipients more frequently received methotrexate and antithymocyte globulin (both P<0.01).

DLBCL was the predominant histologic subtype (17/34), predominantly of activated B-cell subtype. Other histologies included 1 non-destructive PTLD, 2 polymorphic PTLDs, 2 Hodgkin lymphomas, 2 T-cell lymphomas, and 10 other B-cell non-Hodgkin lymphomas.

Two-year OS for the overall cohort was 63.3%. Pediatric liver recipients had the best 2-year OS (91.7%), whereas allo-HSCT and kidney recipients had the poorest 2-year OS (25% and 30%, respectively). Median OS was 4 years for DLBCL, 2.5 months for primary CNS lymphoma, and 4.8 months for T-cell lymphomas, while median OS was not reached for polymorphic and non-destructive PTLD.

Rituximab plus chemotherapy was the most common treatment (21/34). Among DLBCL patients receiving this regimen, median PFS and OS were 2.9 and 6.3 years, respectively. Two patients were treated with reduction of immunosuppression alone: 1 polymorphic PTLD remains in complete remission, whereas 1 Hodgkin Lymphoma relapsed after 10 years.

Among 96 transplant recipients with detectable plasma EBV viral load, 12 developed PTLD. Eight patients received preemptive rituximab for high EBV viral load; none subsequently developed PTLD. The mean EBV viral load among patients who received preemptive Rituximab was 6,760 copies/mL, compared with 955 copies/mL among those who did not receive preemptive treatment. EBER-ISH was positive in 100% of PTLD diagnosed within the first year after transplantation but in only 40% of cases diagnosed ≥5 years after transplantation. The cumulative institutional PTLD incidence was 0.75%, with the highest rates observed after pediatric liver (5.74%) and lung transplantation (5.17%).

Conclusion:

PTLD in this Brazilian cohort demonstrated marked heterogeneity according to transplant type and histologic subtype. Early-onset PTLD after allo-HSCT, lung, and pediatric liver transplantation showed a strong association with EBV, whereas late-onset disease was less frequently EBV-positive. Eight patients with high EBV viral load received preemptive rituximab, and none subsequently developed PTLD, supporting further prospective evaluation of EBV-guided surveillance and preemptive therapy in high-risk transplant recipients. 

Rafael Henneman Sassi, MD: No relevant conflicts of interest to declare.